4-(3,5-dichlorophenyl)-2-(3-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-3,5-dicarboxamide
C20H16Cl2FN5O2 — CID 118061288
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-(3,5-dichlorophenyl)-2-(3-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-3,5-dicarboxamide
4-(3,5-dichlorophenyl)-2-(3-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-3,5-dicarboxamide (PubChem CID 118061288) has the molecular formula C20H16Cl2FN5O2 and a molecular weight of 448.29 g/mol. Its IUPAC name is 4-(3,5-dichlorophenyl)-2-(3-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-3,5-dicarboxamide.
Molecular Properties
| Compound Name | 4-(3,5-dichlorophenyl)-2-(3-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-3,5-dicarboxamide |
|---|---|
| PubChem CID | 118061288 |
| Molecular Formula | C20H16Cl2FN5O2 |
| Molecular Weight | 448.29 g/mol |
| Exact Mass | 447.07 |
| IUPAC Name | 4-(3,5-dichlorophenyl)-2-(3-fluorophenyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-3,5-dicarboxamide |
| SMILES | NC(=O)c1c(-c2cccc(F)c2)nn2c1C(c1cc(Cl)cc(Cl)c1)N(C(N)=O)CC2 |
| InChI | InChI=1S/C20H16Cl2FN5O2/c21-12-6-11(7-13(22)9-12)17-18-15(19(24)29)16(10-2-1-3-14(23)8-10)26-28(18)5-4-27(17)20(25)30/h1-3,6-9,17H,4-5H2,(H2,24,29)(H2,25,30) |
| InChIKey | WRFIFXKFXCMSEW-UHFFFAOYSA-N |
| XLogP | 3.58 |
| TPSA | 107.24 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 448.29 |
| LogP ≤ 5 | 3.58 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118061288 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.